Tags

Type your tag names separated by a space and hit enter

Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients.
Exp Clin Endocrinol. 1988 Aug; 91(3):265-70.EC

Abstract

To estimate the residual beta-cell function, plasma glucose and C-peptide response to an intravenous injection of tolbutamide were observed in seven Type I (insulin dependent) and nine Type II (non-insulin dependent) diabetic patients on insulin therapy. Fasting plasma glucose in the patient was controlled below 11 mmol/l by conventional insulin therapy, and 1 g of tolbutamide was intravenously injected. In the serum C-peptide response following tolbutamide injection, seven of nine Type II diabetics showed the peak values of serum C-peptide more than 0.3 nmol/l from 20 min to 60 min after the load, and Type I diabetics gained the peak values less than 0.3 nmol/l except one patient. The decrease of plasma glucose within 60 min after tolbutamide injection was more than 20% of the basal level in eight of nine Type II diabetics, and in all of seven Type I diabetics the decrease did not exceed 15%. Both serum C-peptide and plasma glucose after tolbutamide load responded differently between Type I and Type II diabetics on insulin therapy, and it was thought that tolbutamide load-glucose response test may be a useful method to estimate the residual beta-cell function in the diabetics.

Authors+Show Affiliations

First Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

3075183

Citation

Mokuda, O, et al. "Plasma Glucose Response After Intravenous Injection of Tolbutamide in Insulin-treated Type I and Type II Diabetic Patients." Experimental and Clinical Endocrinology, vol. 91, no. 3, 1988, pp. 265-70.
Mokuda O, Murakami I, Ikeda T, et al. Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients. Exp Clin Endocrinol. 1988;91(3):265-70.
Mokuda, O., Murakami, I., Ikeda, T., Tominaga, M., & Mashiba, H. (1988). Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients. Experimental and Clinical Endocrinology, 91(3), 265-70.
Mokuda O, et al. Plasma Glucose Response After Intravenous Injection of Tolbutamide in Insulin-treated Type I and Type II Diabetic Patients. Exp Clin Endocrinol. 1988;91(3):265-70. PubMed PMID: 3075183.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients. AU - Mokuda,O, AU - Murakami,I, AU - Ikeda,T, AU - Tominaga,M, AU - Mashiba,H, PY - 1988/8/1/pubmed PY - 1988/8/1/medline PY - 1988/8/1/entrez SP - 265 EP - 70 JF - Experimental and clinical endocrinology JO - Exp Clin Endocrinol VL - 91 IS - 3 N2 - To estimate the residual beta-cell function, plasma glucose and C-peptide response to an intravenous injection of tolbutamide were observed in seven Type I (insulin dependent) and nine Type II (non-insulin dependent) diabetic patients on insulin therapy. Fasting plasma glucose in the patient was controlled below 11 mmol/l by conventional insulin therapy, and 1 g of tolbutamide was intravenously injected. In the serum C-peptide response following tolbutamide injection, seven of nine Type II diabetics showed the peak values of serum C-peptide more than 0.3 nmol/l from 20 min to 60 min after the load, and Type I diabetics gained the peak values less than 0.3 nmol/l except one patient. The decrease of plasma glucose within 60 min after tolbutamide injection was more than 20% of the basal level in eight of nine Type II diabetics, and in all of seven Type I diabetics the decrease did not exceed 15%. Both serum C-peptide and plasma glucose after tolbutamide load responded differently between Type I and Type II diabetics on insulin therapy, and it was thought that tolbutamide load-glucose response test may be a useful method to estimate the residual beta-cell function in the diabetics. SN - 0232-7384 UR - https://www.unboundmedicine.com/medline/citation/3075183/Plasma_glucose_response_after_intravenous_injection_of_tolbutamide_in_insulin_treated_type_I_and_type_II_diabetic_patients_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0029-1210757 DB - PRIME DP - Unbound Medicine ER -